Annals of Hepatology
Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
Mário Reis Álvares-da-Silva; Márcia da Silva Vargas; Soheyla Mohd Souza Rabie; Gabriella Jonko; Patricia Gabriela Riedel; Larisse Longo; Marcelo Rodrigues Gonçalves; Vivian Cristine Luft; Dvora Joveleviths;
10.1016/j.aohep.2024.101584
Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents
Diego García-Compeán; Ramesh Kumar; Ángel Noe del Cueto-Aguilera; Héctor Jesús Maldonado-Garza; Jesús Zacarías Villarreal-Pérez;
Ann Hepatol. 2023;28:
Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease
Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;
10.1016/j.aohep.2024.101589